---
title: "Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264774382.md"
description: "LifeSci Capital analyst Patrick Dolezal has maintained a Buy rating on Structure Therapeutics, Inc. with a price target of $72.00. This rating is based on the promising outlook for its lead product, aleniglipron, and the company's strong financial position, with $800 million in cash. Structure Therapeutics is expected to deliver top-line data from its ACCESS studies by the end of 2025, which could significantly enhance investor confidence. The company is also advancing its pipeline with new studies, indicating a positive future for its stock value."
datetime: "2025-11-07T03:15:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264774382.md)
  - [en](https://longbridge.com/en/news/264774382.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264774382.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264774382.md) | [繁體中文](https://longbridge.com/zh-HK/news/264774382.md)


# Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR yesterday and set a price target of $72.00.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Patrick Dolezal has given his Buy rating due to a combination of factors including the promising outlook for Structure Therapeutics’ lead product, aleniglipron, in the obesity market. The company is on track to deliver top-line data from its ACCESS studies by the end of 2025, which could significantly boost investor confidence if the results align with expectations of a strong product profile. Additionally, the potential for a substantial upside in stock value exists if the clinical outcomes mirror those of competing products, with a projected 100% increase in value.  
Moreover, Structure Therapeutics is advancing its pipeline with the initiation of a first-in-human study for its oral amylin agonist, ACCG-2671, and the development of ACCG-3535, which has shown competitive preclinical results. The company’s robust financial position, with approximately $800 million in cash, is expected to support its operations for over three years, providing a solid foundation for continued research and development. These factors collectively contribute to the positive outlook and the Buy rating assigned by Dolezal.

According to TipRanks, Dolezal is ranked #1345 out of 10072 analysts.

### Related Stocks

- [Structure Therapeutics Inc. (GPCR.US)](https://longbridge.com/en/quote/GPCR.US.md)

## Related News & Research

- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/en/news/281311983.md)
- [3 Best ETFs to Invest In, According to AI Analyst, 03/31/2026](https://longbridge.com/en/news/281217554.md)
- [Rezolve AI 2026 Guidance Suggest 700% Revenue Growth, Analyst Says](https://longbridge.com/en/news/281218944.md)
- [Lattice Acquires Mandala Technology, Advancing the New Way to Work with People + AI](https://longbridge.com/en/news/281231794.md)
- [ThinkLabs AI Inc. announced that it has received $28 million in funding from a group of investors](https://longbridge.com/en/news/281232714.md)